Advanced search
Publication Cover
Climacteric Volume 8, 2005 - Issue sup2: The 11th World Congress on the Menopause
Submit an article Journal homepage
210
Views
0
CrossRef citations to date
0
Altmetric
Abstracts

Book of Abstracts

Pages 1-246 | Published online: 03 Jul 2009

Reference

  • Naftolin, F. Richman, S. Menopause: lack of Darwinian adaptation drives its physiology. In: Schneider HPG and Naftolin F. Climacteric Medicine – where do we go? London: Taylor and Francis, 2005: 4–8.

References

  • Diczfalusy E. The population aging. Ginecol Reprod, 1998;6:122–133.
  • Siseles N, Gutiérrez P, Sayegh F. The climacteric in Latin America: Actual state and future trends. In: The Meno-pause at the Millennium. The Proceedings of the 9[sup]th [/sup]International Menopause Society World Congress on the Menopause. Yokohama, Japan. The Parthenon Publishing Group New York, London; 2000, 108–116.
  • Siseles N, Gutiérrez P. Do different cultures really explain different attitudes to the management of the menopause? Medicographia 2001; 23 (4): 313–314.
  • Artiles Visbal L et al. Gender impact in the Climacterium, CIMEQ´ 99. Havana, Cuba; 1999.
  • Barnett EA. Perceptions of menopause: Importance of role satisfaction in a Peruvian town. California, Stanford University, 1986. In: SennottMiller Lee. Health and Socioeconomic situation of midlife and elderly women in Latin America and Caribe. In: Midlife and elderly women in Latin America and Caribe. PAHO/WHO, 1990:3–130.

References:

  • Russo J, Calaf G, Russo IH. A critical approach to the malignant transformation of human breast epithelial cells. CRC Critical Reviews in Oncogenesis 1993;4:403–417.
  • Calaf G, Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 1993;14:483–492.
  • Russo J, Lareef MH., Balogh G, Guo S, Russo I.H. Estrogen and its metabolites are carcinogenic in human breast epithelial cells. J. of Steroid Biochemistry & Molecular Biology 2003;87:1–25.

Reference

References

References

  • Carr M. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404–2411.
  • Berg G, Mesch V, Boero L, et al. Lipid and lipoprotein profile throughout the menopausal transition. Effects of hormones, age and central obesity. Horm Metab Res 2004,36:215–220.
  • Berg G, Siseles N, Gonzalez A et al. Higher values of Hepatic Lipase activity in postmenopause. Menopause 2001;8(2):51–57.
  • Carr M, Kim K, Zambon A et al. Changes in LDL density across the menopausal transition. J Investig Med. 2000;48(4):245–50.
  • Berg G, Muzzio ML, Wikinski R, Shreier L. A quantitative dense LDL subfraction measurement. Nutr Metab Cardiov Diseas 2004;14(2):73–80.

References

  • Day D et al Sex Hormone Suppression Reduces Resting Energy Expenditure and ß-Adrenergic Support of Resting Energy Expenditure JCEM 2005. 90,3312–3317.
  • Gallagher D et al: Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 2000.279: E366–E375.
  • Salpeter SR et al Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804.
  • Livingstone C and Collison M Sex steroids and insulin resistance. Clinical Science. 2002. 102. 151–166.
  • UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.

References

  • Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2947–58.
  • Yaffe, K, Sawaya G, Lieberburg, et al. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998;279:688–95.
  • Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000;21:373–83.

References

  • Rymer J, Morris EP. ‘‘Extracts from ‘‘Clinical evidence’’: Menopausal symptoms. Bmj 2000;321(7275):1516–9.
  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 2002;288(3):321–33.
  • Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without proges-tins. J Natl Cancer Inst 1999;91(13):1131–7.
  • Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Bjog 2000;107(11):1392–400.
  • Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49(1):56–72.
  • Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000(2):CD002126.
  • Guillebaud J. The levonorgestrel intrauterine system: a clinical perspective from the UK. Ann N Y Acad Sci 2003;997:185–93.
  • Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNGIUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005.
  • Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7(12):1133–44.
  • Erel CT, Seyisoglu H, Senturk ML, Akman C, Ersavasti G, Benian A, et al. Mammographic changes in women on hormonal replacement therapy. Maturitas 1996;25(1):51–7.
  • Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40(2):151–7.

References

References

  • Abrams P, et al., editors. Incontinence: proceedings from the second international consultation on incontinence. Plymouth, UK: Health Publications, Inc.; 2002.
  • wart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327–36.
  • Hannestad Y, Rortveit G, Hunskaar S. A community-based epidemiological survey of female urinary incontinence. The Norwegian EPINCONT study. Poster. International Continence Society 30th Annual Meeting Tampere Hall, Tampere, Finland August 28–31, 2000.
  • Sand PK, Dmochowski R. Analysis of the Standarization of terminology of lower urinary tract dysfunction: Report from the standarization sub-committee of the International Continence Society. Neurourol Urodynam 21: 167–78, 2002.
  • Fultz NH et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol. 2003; November: 1275–1282.
  • Castro-Diaz et al. Pharmacotherapy for stress urinary incontinence. Current Opinion in Urology. 15(4):227–230, July 2005.
  • Sweeney D, Chancellor M Treatment of Stress Urinary Incontinence with Duloxetine Hydrochloride Rev Urol. 2005;7(2):81–86.
  • Pickard R , Reaper J, Wyness L, Cody DJ, McClinton S, N’Dow J. Periurethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2003; (1):CD003881.

References

  • Lusis A J. Atherosclerosis. Nature 2000;107:233–241.
  • Berg G, Siseles N, Gonzalez A, Contreras O, Tempone A, Wikinski R. Higher values of Hepatic Lipase activity in postmenopause. Menopause 2001;8(2):51–57
  • Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–126.
  • Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, Wikinski R, Schreier L. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004;177:203–210.

References

References

  • Eisman J, Clapham S, Kehoe L, Osteoporosis Prevalence and Levels of Treatment in Primary Care: The Australian BoneCare Study, J Bone Miner Res 2004;19:1969–1975.
  • Simonelli SC, Killeen K Mehle S, Swanson L, Barriers to Osteoporosis Identification and Treatment Among Primary care Physicians and Orthopedic Surgeons, Mayo Clin Proc. 2002;77:334–338.
  • Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J, Osteoporotic Fracture: Missed Opportunity for Intervention, Osteoporos Int 2003;14:780–784.

References

  • D. Keefe, L.M. Garcia-Segura and F. Naftolin, New insights into estrogen action on the brain. Neurobiol. Aging 1994;15:495–497.
  • D.W. Pfaff. Estrogen and Brain Function (first ed.),, Springer, New York (1980).
  • V.W. Henderson. Hormone Therapy and the Brain (first ed.),, Parthenon Publishing, New York (1999).
  • C.Y. Pau, K.Y. Pau and H.G. Spies, Putative estrogen receptor beta and alpha mRNA expression in male and female rhesus macaques. Mol. Cell. Endocrinol 1998;146:59–68.
  • M.X. Tang, D. Jacobs, Y. Stern et al., Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.
  • I. Bechmann, G. Mor, J. Nilsen et al., FasL (CD95L, APO1L) is expressed in the normal rat and human brain evidence for the existence of an immunological brain barrier. Glia 1999;27:62–74.

References

  • Ibanez L, Dimartine-Nardi J, Potau N, Saenger P. 2000. Premature adrenarche – normal variant or forerunner of adult disease? Endocrine Reviews 21: 671–696
  • Parker LN, Odell WD. 1980. Control of adrenal androgen secretion. Endocr Rev 4: 392–410.
  • Liu CH, Laughlin GA, Fischer UG, Yen SSC. 1990. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20 desmolase enzymatic activity. J Clin Endocrinol Metab 71: 900–906.
  • Phillips GB. 1996. Relationship between serum dehydroepiandrosterone sulfate, androstenedione, and sex hormones in men and women. Eur J Endocrinol 134: 201–206.
  • Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M. 1998. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab 83: 1–5.
  • Stomati M, Casarosa E, Bernardi F, Tonetti A, Genazzani AD, Luisi M, Genazzani AR. 2001. DHEA and andro-pause. In Diagnostic procedure and latest development in Gynecologic and Obstetric Investigation, Genazzani AR, Artini PG, D’Ambrogio G, Gadducci A, Gambacciani M, Genazzani AD Eds., CIC Edizioni Internazionali, Roma, Italy, pp 102–110.
  • Paul SM, Purdy RH. 1992. Neuroactive steroids. FASEB J 6: 2311–2322.
  • Morales AJ, Nolan JJ, Nelson JC, Yen SSC. 1994. Effects of replacement dose of DHEA in men and women of advancing age. J. Clin Endocrinol Metab 78: 1360–1367
  • Bernardi F, Pieri M, Stomati M, Luisi S. Palumbo M, Pluchino N, Ceccarelli C, Genazzani AR. 2003. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol 17: 65–77
  • Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. 2001. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 76: 241–248.

References

  • Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004;11:749–765.
  • Davis S, Tran J. Testosterone influences libido and well-being in women. Trends Endocrinol Metab 2001;12:33–37.
  • Davison S, Bell R, Donath S, Montalto J, Davis S. Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 2005;
  • Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003;188:286–293.
  • Nappi RE, Detaddei S, Ferdeghini F, Brundu B, Sommacal A, Polatti F. Role of testosterone in feminine sexuality. J Endocrinol Invest 2003;26:97–101.
  • Rosen R, et al eds. Androgen Insufficiency in women: the Princeton Conference. Fertil Steril 2002; 77, Suppl 4.

References

  • Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003;51(19):5661–5670.
  • Chopin Lucks B. Vitex agnus castus essential oil and menopausal balance: a research update. Complement Ther Nurs Midwifery. 2003;9(3):157–160.
  • McMillan TL, Mark S. Complementary and alternative medicine and physical activity for menopausal symptoms. JAMWA. 2004;59:270–277.
  • Chenoy R, Hussain S, Tayob Y, O’Brien PM, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308(6927):501–503.
  • Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137(10):805–813.
  • Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4(2):144–150.
  • Radix Angelicae Sinensis. Geneva, Switzerland: WHO; 2001.
  • Russell L, Hicks GS, Low AK, Shepherd JM, Brown CA. Phytoestrogens: a viable option? Am J Med Sci. 2002;324(4):185–188.
  • Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981–986.

References

  • Bell S.E. Changing ideas: the medicalization of menopause. Soc.Sci Med (1987) 6:535–542.
  • Romm J. Sexuality during the Perimenopause. Current Women’s Health Reports (2003);3:470–474.
  • CEPAL America Latina y el Caribe: el envejecimiento de la población. 1950–2050. Boletín Demográfico. Centro Latinoamericano y Caribeño de Demografía (CELADE). Santiago de Chuile. 2003.
  • Hunter M. The Women’s Health Questionnaire : A Measure of Mid-Aged Women’s Perceptions of Their Emotional and Physical Health. Psychology and Health 1992;7:45–54.
  • Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996 Jul;24(3):161–75.
  • Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000 Mar;3(1):59–64.
  • Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Meno-pause. 2002 Nov-Dec;9(6):402–10.
  • Grupo Cervantes. Escala Cervantes. Escala de Calidad de Vida para la mujer menopáusica española. Organon, Barcelona, 2004.

References

  • Habiba MA, Bell SC, Al-Azzawi F. The effect of hormone replacement therapy on the immunoreactive concentrations in the endometrium of oestrogen and progesterone receptor, heat shock protein 27 and human beta-lactoglobulin. Human Reprod 2000;15(1):36–42.
  • Hickey M, Higham J, Sullivan M, Miles L, Fraser IS. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP – 9) and tissue inhibitors of MMPs. Fertil Steril 2001;75(2):288–96.
  • Dahmoun et al Apoptosis, proliferation and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas 2004;49:114–123.

References

  • Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding–a Nordic multicenter study. Am J Obstet Gynecol 1995;172(5):1488–94.
  • Iatrakis G, Diakakis I, Kourounis G, Sakellaropoulos G, Rammos G, Ladopoulos J, et al. Postmenopausal uterine bleeding. Clin Exp Obstet Gynecol 1997;24(3):157.
  • Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heinz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996;87(3):345–9.
  • Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. Jama 1998;280(17):1510–7.
  • Goldstein RB, Bree RL, Benson CB, Benacerraf BR, Bloss JD, Carlos R, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultra-sound-Sponsored Consensus Conference statement. J Ultrasound Med 2001;20(10):1025–36.
  • Ferrazzi E, Torri V, Trio D, Zannoni E, Filiberto S, Dordoni D. Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study. Ultrasound Obstet Gynecol 1996;7(5):315–21.
  • Sheikh M, Sawhney S, Khurana A, Al-Yatama M. Alteration of sonographic texture of the endometrium in post-menopausal bleeding. A guide to further management. Acta Obstet Gynecol Scand 2000;79(11):1006–10.
  • Affinito P, Palomba S, Pellicano M, Sorrentino C, Di Carlo C, Morgera R, et al. Ultrasonographic measurement of endometrial thickness during hormonal replacement therapy in postmenopausal women. Ultrasound Obstet Gynecol 1998;11(5):343–6.
  • Langer RD, Pierce JJ, O’Hanlan KA, Johnson SR, Espeland MA, Trabal JF, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 1997;337(25):1792–8.
  • Kamel HS, Darwish AM, Mohamed SA. Comparison of transvaginal ultrasonography and vaginal sonohysterography in the detection of endometrial polyps. Acta Obstet Gynecol Scand 2000;79(1):60–4.

References

  • Spitz IM. Preface: Progestins, Progesterone Receptor Modulators and Progesterone Antagonists. Steroids 2000;65:543–544.
  • Gravanis A, Schaison G, George M, et al. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985;60:156–63.
  • Hodgen GD, van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994; 9 Suppl 1:77–81.
  • Chwalisz K, Brenner RM, Fuhrmann U, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65:741–751.
  • Narvekar N, Cameron S, Critchley H, Lin S, Cheng L, Baird D. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491–7.
  • Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab. 2003;88(2):946–9.

References

  • Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333(5):276–282.
  • Food labeling: Health Claims; Soy Protein and Coronary Heart Disease. Federal Register: October 26, 1999. Vol 64;1999:57699–57733.
  • Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Meno-pause. 2001;8(4):259–265.
  • Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005;90(3):1390–1397.
  • Flynn A. The role of dietary calcium in bone health. Proc Nutr Soc. 2003;62(4):851–858.
  • Macdonald HM, New SA, Fraser WD, Campbell MK, Reid DM. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr. 2005;81(4):923–933.
  • Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004;79(2):326–333.
  • Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol. 2001;97(1):109–115.
  • Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002(4):CD003120.
  • Tode T, Kikuchi Y, Hirata J, Kita T, Nakata H, Nagata I. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. Int J Gynaecol Obstet. 1999;67(3):169–174.
  • McDaniel MA, Maier SF, Einstein GO. ‘‘Brain-specific’’ nutrients: a memory cure? Nutrition. 2003;19(11–12):957–975.

References

  • Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–874.
  • Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–1143.
  • Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169:203–214.
  • Register TC, Cann JA, Kaplan JR, Williams JK, Adams MR, Morgan TM, Anthony MS, Blair RM, Wagner JD, and Clarkson TB. Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J Clin Endocrinol Metab 2005;90:1734–1740.
  • Kitamoto S, Nakano K, Hirouchi Y, Kohjimoto Y, Kitajima S, Usui M, Inoue S, Egashira K. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol 2004;24:1522–1528.

References

  • De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen AS. The first uterine pass effect. Ann N Y Acad Sci. 1997;26(828):291–299.
  • Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95(3):403–406.
  • Sitruk-Ware R, Small M, Kumar N, Tsong YY, Sundaram K, Jackanicz T. Nestorone® Clinical applications for contraception and HRT Steroids. 2003;68:907–913.
  • Sitruk-Ware R, Small M: endometrial protection with the levonorgestrel-releasing intrauterine system during estrogen replacement therapy. Gynecology Forum 2003;8:19–22.

References

  • Neven P. New SERMs in development. European Journal of Cancer 2002;38 (Suppl 6):S26–S27.
  • Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 1997;227:1508–1510.
  • Yaffe K, Krueger K, Sarpar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207–1213.
  • McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003;90:64–69.
  • Riggs BL and Hartmann LC. Selective Estrogen-Receptor Modulators. Mechanism of Action and Application to Clinical Practice. N Engl J Med 2003;348:618–629.

References

References

  • Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002;143:205–212.
  • Gonzalez Deniselle MC, Lopez-Costa JJ, Saavedra JP, Pietranera L, Gonzalez SL, Garay L, Guennoun R, Schumacher M, De Nicola AF. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol Dis 2002;11:457–468.
  • Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002;178:59–67.
  • Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003;53:390–391.
  • Melcangi RC, Azcoitia I, Ballabio M, Cavarretta I, Gonzalez LC, Leonelli E, Magnaghi V, Veiga S, Garcia-Segura LM. Neuroactive steroids influence peripheral myelination: a promising opportunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol 2003;71:57–66.
  • Mellon SH, Griffin LD. Synthesis, regulation, and function of neurosteroids. Endocr Res 2002;28:463.
  • Frye CA, Scalise TJ. Anti-seizure effects of progesterone and 3alpha,5alpha-THP in kainic acid and perforant pathway models of epilepsy. Psychoneuroendocrinology 2000;25:407–420.
  • Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002;143,205–212.

Reference

  • Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier (IBB). Glia 1999;27(1):62–74.

Reference

  • Russo, J., Mailo, D., Hu, Y-F., Balogh, G.A., Sheriff, F., Russo, I. H. Breast differentiation and its implication in cancer prevention. Clinical Cancer Research 2005;11:931s–936s.

References

  • Herrington DM, Howard TD, Hawkins GA et al. Estrogen receptor polymorphisms and effects of estrogen replacement on HDl cholesterol in women with coronary disease. N Engl J Med 2002;346:967–974.
  • Herrington DM, Howard TD, Brosnihan KB et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879–1882.

References

  • Holmberg L, Andersson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomized comparison stopped. Lancet 2004;363:453–5.
  • von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer; the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533–5.

References

  • Seidell JC. Obesity in Europe. Obes Res. 1995 Sep;3 Suppl 2:89s–93s
  • Lean MEJ, et al. Obesity–what are the current treatment options? Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:22–6
  • Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37; 1955–1607
  • Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care 2002; 8 (suppl 11): 5283–5296
  • Beck-Nielsen H. General characteristics of the insulin resistance syndrome prevalence and heretability. European Group for the Study of Insulin Resistance. Drug 1999;58 (suppl 1):7–10

References

  • Elsaesser A, Hamm CW. Acute coronary syndrome: the risk of being female. Circulation 2004;109:565–7.
  • Sutton-Tyrrell K, Wildman RP, et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005;111:1242–9.

References

  • Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, et al. 1992 Molecular and biological characterization of a murine ligand for CD40. Nature 357, 80–82.
  • Mor G, Nilsen J, Horvath T, Bechmann I, Brown S, Garcia-Segura LM, Naftolin F. 1999. Estrogen and Microglia: A regulatory system that affect the brain.
  • Bechmann I, Mor G, Nilsen, et al 1999. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain-evidence for the existence of an immunological brain barrier. Glia 27:62–74.
  • Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M, 1999. Microglial Activation Resulting from CD40-CD40L Interaction After b-Amyloid stimulation. Science 286:2352–55.
  • Nilsen J Mor G, Naftolin F, 2000. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol. 43(1):64–78, 2000.

References

References

  • Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipo-proteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777–780.
  • Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein AI, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;15;358:2026–2033.
  • Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990;75:217–222.
  • Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001;86:5396–5404.
  • Mikkola TS, Anthony MS, Clarkson TB, St. Clair RW. Serum cholesterol efflux in postmenopausal monkeys treated with tibolone or conjugated estrogens. Metabolism 2002;51(4):523–530.

References

  • Stevenson JC. Metabolic effects of the menopause and oestrogen replacement. In: Barlow DH, ed. Baillière’s Clinical Obstetrics and Gynaecology. The menopause: key issues. London: Ballière Tindall, 1996: 449–67.
  • Stevenson JC. Lipid metabolism. In: Genazzani AR, ed. Hormone replacement therapy and cardiovascular disease. Carnforth: Parthenon Publishing, 2001: 27–35.
  • Stevenson JC. The metabolic basis for the effects of HRT on coronary heart disease. Endocrine 2004;24:239–44.

References

  • Ganz PA, Desmond KA, Belin TR et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371; 1999.
  • Day R, Ganz PA, Costantino JP et al. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659; 1999.
  • Modugno F, Bess RB, Ewing S et al. Effect of raloxifene on sexual function in older women with osteoprosis. Obstet Gynecol 101:353; 2003.
  • Kessel B, Nachtigall L, Plouffe L et al. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 6:248; 2003.
  • Simon J, Gass M, Kagan, R et al. Lasofoxifene effectively treats dyspareunia in postmenopausal women with vaginal atrophy. Obstet Gynecol 105:2S; 2005 (abs).

Bibliography

  • Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004;11:749–765.
  • Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Meno-pause. 2004;11:120–130.
  • Basson R. Introduction to special issue on women’s sexuality and outline of assessment of sexual problems. Menopause 2004;11:709–13.
  • Davis SR, Burger H. Androgen and postmenopausal women. J Clin Endocrinol Metab 1996;81:2759–2763.
  • Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162–170.
  • Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–358.
  • Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77:S42-S48.
  • Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003;188:286–293.
  • Nappi RE, Baldaro Verde J, Polatti F, Genazzani AR, Zara C. Self-reported sexual symptoms in women attending menopause clinics. J Obstet Gynecol Invest 2002;53:181–187.
  • Nappi RE, Detaddei S, Ferdeghini F, Brundu B, Sommacal A, Polatti F. Role of testosterone in feminine sexuality. J Endocrinol Invest 2003;26:97–101.
  • Sarrel PM. Sexuality and menopause. Obstet Gynecol 1990;75:26S-35S.

References

  • Castelo-Branco C, Duran M, Gonzalez-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas. 1992;15:113–119.
  • Brincat M, Kabalan S, Studd JWW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness and bone mass in the postmenopausal woman. Obstet Gynecol. 1987;70:840–845.
  • Brincat M, Moniz CF, Kabalan S, Versi E, O’Dowd T, Magos AL, Montgomery J, Studd JWW. Decline in skin collagen content and metacarpial index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynecol. 1987; 94 (2): 126–129.
  • Castelo-Branco C, Pons F, Gratacós E, Fortuny A, Vanrell JA, González-Merlo J. Relationship between skin collagen and bone changes during aging. Maturitas. 1994;18:199–206.

References

  • Whitmer RA et al. Midlife cardiovascular risk factors and risk of dementia in late life Neurology. 2005;64(2):277–81.
  • Pappolla MA et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61(2):199–205.

References

  • Riggs L, Khosla S, Melton J. Sex steroids and the construction and conservation of adult skeleton. Endocrine Reviews. 2002;22:279–302.
  • Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Jones M, Davis S. The role of local estrogen biosynthesis in males and females.Trends Endocrinol Metab. 2000;11:184–88.
  • Kousteni S, Bellido T, Plotkin L, O’brien C, Bodenner D, et al. Nongenomic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719–30.
  • Vanderschueren D, Vandenput L, Boonen S, Lindberg M, Bouilon R, Ohlsson C. Androgens and bone. Endocrine Reviews. 2004; 25: 389–425.
  • Khosla S, Bilezikian J. The role of estrogen in men and androgen in women. Endocrinol Metab Clin N Am. 2003;32:195–218.

References

  • Bachmann G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660–5.
  • Rannevik G, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103–113.
  • Sherwin B, Gelfand M. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinol 1985;10:325–335.
  • Lobo R, et al. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341–52.
  • Arlt W, et al. Dehydroepiandrosterone replacement in women with adrenal insuficiency. N Engl J Med 1999;341:1013–20.
  • Morales A, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360–1367.
  • Davis S, et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–236.
  • Shifren J, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–8.
  • Buster JE, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obset Gynecol 2005;105:944–52.

References

  • Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 2004;104:443–51.
  • Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042–8.
  • Johnson S, Ettinger B, Ensrud K, Wallace R, et al. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779–87.

References

  • Kenemans P, Speroff L. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21–28.
  • Holmberg L., Andersson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–5.
  • Schoultz E von, Rutqvist LE on Behalf of the Stockholm Breast Cancer Study Group. Menopausal Hormone Therapy After Breast Cancer: The Stockholm Randomized Trial. J Nat Cancer Inst 2005;97:533–535.
  • Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obst Gynec 2005;112:228–233.

References

  • Rymer J, Chapman MG, Fogelman I, Wilson, POG. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994;18:127–33.
  • Genazzani AR, Benedeck-Jaszman LJ, Hart DM, et al. Effects of Org OD14 on pituitary and beta-endorphins in castrated rats and in postmenopausal women. Maturitas. 1987;Suppl.1:35–48.
  • Nathorst-Boos J, Hammar M. Effect on sexual life – a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15–20.

References

  • Hickey M, Higham J, Sullivan M, Miles L, Fraser IS 2001 Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertility & Sterility. 75:288–96.
  • Hickey M, Pillai G, Higham JM, et al. 2003 Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Human Reproduction. 18:1100–6.
  • Hickey M, Crewe, J, Goodridge, J,P, Witt, C,S, Fraser, I,S, Doherty, D, Christiansen, F,T, Salamonsen, L, A 2005 Menopausal hormone therapy and irregular endometrial bleeding: A potential role for uterine natural killer cells? JCEM, in press.

References

  • Suckling J, Lethaby A. Local Estrogen for Vaginal Atrophy. Cochrane database Syst Rev 2003; (4) CD1500.
  • Bachmann GA, Nevadunsky N. Diagnosis & Treatment of Atrophic Vaginitis. Amer Fam Physician 2000;61:3090–6.
  • Nieman LK. Management of Hypogonadal patients unable to tale HRT. Endocr & Metab Clinics of NA 2003;32(2):325–36.
  • Weisberg E, Ayton Retal. Endometrial & Vaginal effects of Estradiolby Ring or Vaginal tablet. Climacteric 2005;8:83–92.

References

  • Abrutyn E, Boscia JA, Kaye D. The treatment of asymptomatic bacteriuria in the elderly. J Am Geriatr Soc 1988;36:473–5.
  • Sourander LB. Urinary tract infection in the aged – an epidemiological study. Am Med Intern Fenn 1966;55(45):7–55.
  • Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infection in postmenopausal women – a multi-factorial condition. Clin Infect Dis 2000;30:152–6.
  • Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753–6.
  • Brocklehurst JC, Dillane JB, Griffiths L, Fry J. The prevalence and symptomatology of urinary infection in an aged population. Gerontol Clin 1968;10:242–53.
  • Wolfdon SA, Kalmanson GM, Rubini ME, Guze LB. Epidemiology of bateriuria in a predominantly geriatric male population. Am J Med Sci 1965;250:168–73.
  • Brocklehurst JC, Bee P, Jones D et al. Bacteriuria in geriatric hospital patients, its correlates and management. Age Ageing 1977;6:240–5.
  • Boscia JA, Kobasa WD, Abruptyn E et al. Lack of association between bacteriuria and symptoms in the elderly. Am J Med 1986;81:979–82.

References

  • Blumenthal, M. (ed.) Herbal Medicine: Expanded Commision E Monographs. Newton, MA: Integrative Medicine Communications; 2003.
  • Tode T, Kikuchi Y, Hirata J, Kita T, Nakata H, Nagata I. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. Int J Gynaecol Obstet. 1999;67(3):169–174.
  • Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985;87(4):406–409.
  • Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol. 2000;20(1):84–89.
  • Mahady GB. Is black cohosh estrogenic? Nutr Rev. 2003;61(5 Pt 1):183–186.
  • Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003;51(19):5661–5670.
  • Winterhoff H, Spengler B, Christoffel V, Butterweck V, Lohning A. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. Maturitas. 2003;44 Suppl 1:S51–58.
  • Linde K, Ramirez G, Mulrow CD, Pauls A, Weiden-hammer W, Melchart D. St John’s wort for depression–an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313(7052):253–258.
  • Linde K, Berner M, Egger M, Mulrow C. St John’s wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry. 2005;186:99–107.
  • Liske E. Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Ther. 1998;15(1):45–53.
  • Gardner C. Ease through menopause with homeopathic and herbal medicine. J Perianesth Nurs. 1999;14(3):139–143.

References

  • Bromberger, J.T., Meyer, P.M., Kravitz, H.M., Sommer, B., Cordal, A., Powell, L., Ganz, P.A., and Sutton-Tyrrell, K.: Psychologic distress and natural menopause: a multiethnic community study. Am. J. Public Health 2001;91:1435–1442.
  • Freeman, E.W., Sammel, M.D., Liu, L., Gracia, C.R., Nelson, D.B., and Hollander, L.: Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch. Gen. Psychiatry 2004;61:62–70.
  • Schmidt, P.J., Murphy, J.H., Haq, N., Danaceau, M.A., and Simpson St.Clair, L.: Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002;27:907–920.
  • Schmidt, P.J., Nieman, L., Danaceau, M.A., Tobin, M.B., Roca, C.A., Murphy, J.H., and Rubinow, D.R.: Estrogen replacement in perimenopause-related depression: a preliminary report. Am. J. Obstet. Gynecol 2000;183:414–420.
  • Soares, C.D. and Almeida, O.P.: Depression during the perimenopause. Arch. Gen. Psychiatry 2001 58:306.
  • Schmidt, P.J., Haq, N.A., Rubinow, D.R.: A long-itudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am. J. Psychiatry 2004;161:2238–2244.
  • Berman, K.F., Schmidt, P.J., Rubinow, D.R., et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc. Natl. Acad. Sci. U. S. A. 1997;94:8836–8841.

References

  • Lobo, Rogerio A. Early ovarian ageing: a hypothesis. Hum. Reprod 2003;18:1762–1764.
  • Faddy, MJ, Gosden, RG, Gougeon, A, Richardson, SJ, Nelson, JF. Accelerared disappearance of ovarian follicles in mid- life: implications for forecasting menopause. Hum. Reprod 1992;7:1342–1346.
  • Nikolau, D and Templeton, A. Early ovarian ageing: a hypothesis. Hum. Reprod 2003;18:1137–1139.
  • Hansen, KR, Thyer, AC, Sluss, P, Bremmer, W, Soules, MR, Klein, NA. Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum. Reprod 2004;20:89–95.
  • De Vet, A, Laven, JS, de Jong, FH, Themmen, AP, Fauser, BC. Antimullerian hormone serum levels: a putative marker for ovarian ageing. Feril Steril 2002;77:357–362.
  • Wallace WH , Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum. Reprod 2004;19:1612–1617.
  • Sharara FI, Scott RT. Assessment of ovarian reserve. Is there still a role for ovarian biopsy? First do no harm! Hum Reprod 2004;19:470–471.

References

  • Clarkson TB, Appt SE. Controversies about HRT – lessons from monkey models. Maturitas 2005;51:64–74.
  • Merz CN, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE Study. J Am Coll Cardiol 2003;41:413–19.
  • Merz CN, et al. 14[sup]th [/sup]Annual Meeting of the North American Menopause Society, P-51:87 (abstract).
  • Salpeter SR, et al. Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med 2004;19:791–804.

References

  • Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol Endocrinol 1998;12(12):1939–1954.
  • Norris JD, Paige LA, Christensen DJ et al. Peptide antagonists of the human estrogen receptor. Science 1999;285(5428):744–746.
  • Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276(38):35684–35692.
  • Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98(1):36–42.
  • Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 2000;141(9):3403–3411.
  • Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 2000;97(11):5930–5935.
  • Herrington DM, Howard TD, Hawkins GA et al. Estrogen receptor polymorphisms and effects of estrogen replacement on HDl cholesterol in women with coronary disease. N Engl J Med 2002;346:967–974.
  • Griffin JE, Wilson JD. The syndromes of androgen resistance. N Engl J Med 1980;302:198–209.
  • Armanini D, Kuhnle U, Strasser T et al. Aldosterone-receptor deficiency in pseudohypoaldosteronism. N Engl J Med 1985;313:1178–1181.
  • Pike JW, Dokoh S, Haussler MR, Liberman UA, Marx SJ, Eil C. Vitamin D3-resistant fibroblasts have immunoassayable 1,25-dihydroxyvitamin D3 receptors. Science 1984;224:879–881.
  • Gehring U, Tomkins GM. A new mechanism for steroid unresponsiveness: loss of nuclear binding activity of a steroid hormone receptor. Cell 1974;3:301–306.
  • Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996;94:727–733.

References

  • Anasti JN. Premature ovarian failure: an update. Fertil. Steril 1998,70:1–15.
  • Laml T, Schultz-Lobmeyr I, Obruca A, et al. Premature ovarian failure: etiology and prospects, in Gynecol Endocrinol 2000;14:292–302.
  • Luborsky, JL, Meyer, P, Sowers, MF, Gold, EB, Santoro, N. Premature menopause in a multiethnic population study of the menopause transition. Hum Reprod 2003;8(1):199–206.
  • Adamopoulos DA, Karamertzanis MD, Thomopoulos A, Pappa A, Koukkou E. Nicopoulou SC. Age at menopause and prevalence of its different types in contemporary Greek women. Menopause 2002;9(6):443–448.
  • Progetto Menopausa Italia Study Group (including Graziottin A.) Premature ovarian failure: frequency and risk factors among women attending a network of Menopause Clinics in Italy Br J Obstet Gynecol 110: 59–63; 2003
  • Graziottin A. Sexuality, ageing and chronic diseases: iatrogenic premature menopause in cancer survivors. In: Schneider HPG, ed. Menopause: the state of the art, London, UK: Parthenon Publishing, 2003:408–415.
  • Graziottin A. Basson R. Sexual Dysfunctions in women with Premature Menopause Menopause, 11 (6): 766–777, 2004
  • Dennerstein L. Koochaki P.E. Barton I. Graziottin A. Surgical menopause and female sexual functioning: a survey of western european women Menopause (in press)

References

  • Drench ME, Losee RH. Sexuality and sexual capacities of elderly people. Rehabil Nurs 1996;21:118–123.
  • Laumann EO, Paik A, Rosen RC. Sexual Dysfunction in the United States. Prevalence and Predictors. JAMA 1999;281:537–44.
  • McCoy NL. Methodological problems in the study of sexuality and the menopause. Maturitas 1998;29:51–60.
  • Borissova AM, Kovatcheva R, Shinkov A. Changes in sexual behavior in Bulgarian women after the meno-pause. Gynecol Endocrinol 2000;14:448–53.
  • Avis NE, Stellato R, Crawford S, Johannes C, Long-cope C. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297–309.
  • Blumel JE, Castelo-Branco C, Binfa L, Gramegna G, Tacla X, Aracena B, Cumsille MA, San Juan A. Quality of life after the menopause: to population study. Maturitas 2000;34:17–23.
  • Hidalgo L, Chedraui P, Morocho N, Alvarado M, Chavez D, Huc A. [Evaluation of quality of life in a female ecuadorian population]. Rev Medicina 2005; In press.
  • Yanez L, Hidalgo L, Chedraui P. [Sexual dysfunction and risk factors involved in a female ecuadorian climacteric population]. Rev Medicina 2005; In press.
  • Castelo-Branco C, Blumel JE, Araya H, Riquelme R, Castro G, Haya J, Gramegna G. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003;23:426–30.
  • Sierra B, Hidalgo LA, Chedraui PA. Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale. Maturitas 2005;In press.
  • Blumel JE, Castelo-Branco C, Riquelme R, Araya H, Jaramillo P, Tacla X et al. Use of hormone replacement therapy among Chilean women: a comparison between socioeconomic levels. Menopause 2002;9:377–80.
  • Gramegna G, Blumel JE, Roncagliolo ME, Aracena B, Tacla X. [Patterns of sexual behavior in Chilean women]. Rev Med Chil 1998;126:162–8.
  • Kirchengast S. [Effect of socioeconomic factors on timing of menopause and the course of climacteric]. Z Gerontol 1992;25:128–33.

References

  • Avis NE, Brambilla D, McLinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression – results from the Massachusetts Women’s Health Study. Ann Epidemiol 1994;4:214–220.
  • Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosomatic Med 1999;61:676–697.
  • Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and Menopausal Status as Predictors of Depression in Women in Transition to Menopause. Arch Gen Psychiatry 2004;61:62–70.
  • Halbreich U & Lumley LA. The multiple interactional biological processes that might lead to depression and gender differences in its appearance. J Affect Disord 1993;29:159–173.
  • Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003;60:29–36.
  • Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414–420.
  • Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238–2244.
  • Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336–343.
  • Steiner M & Yonkers K. Depression in women. Martin Dunitz Ltd, London, UK, 1998.
  • Sundstrom IM, Bixo M, Bjorn I, Astrom M. Prevalence of psychiatric disorders in gynecologic outpatients. Am J Obstet Gynecol 2001;184:8–13.

References

References

  • Cramer JA, Spilker B. Quality of Life & Pharmacoeconomics: an Introduction. 1998 by Lippincott-Raven.
  • ICH Guideline for Good Clinical Practice. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use.
  • Girod I, Abetz L, de La Loge C, Fayol-Paget C. Women’s Health Questionnaire User Manual (2004). Available at www.igod.org/Instruments files/USERS/whq.zip.
  • Draft Guidance: Estrogen and Estrogen/progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommendations for Clinical Evaluation. US Department of Health and Human Services. FDA. CDER. January 2003 (www.fda.gov/cder/guidance/5412dft.doc)

References

References

References

  • Cramer J, et al. J Bone Miner Res 2004;19 (Suppl. 1):S448 (Abstract M434).
  • Recker RR, et al. J Bone Miner Res 2004;19 (Suppl. 1):S172 (Abstract SA407).
  • Chesnut CH, et al. J Bone Miner Res 2004;19:1241–9.

References

  • Christenson LK, Devoto L. Cholesterol transport and steroidogenesis by the corpus luteum. Reprod Biol Endocrinol. 2003 Nov 10;1(1):90.
  • Burger HG. Androgen production in women. Fertil Steril. 2002 Apr;77 Suppl 4:S3–5.
  • Dharia S, Parker CR Jr. Adrenal androgens and aging. Semin Reprod Med. 2004 Nov;22(4):361–8
  • Sluijmer AV, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab. 1995 Jul;80(7):2163–7.
  • Jabara S, Christenson LK, Wang CY, McAllister JM, Javitt NB, Dunaif A, Strauss JF 3rd. Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype. J Clin Endocrinol Metab. 2003 Jan;88(1):484–92.
  • Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab. 2001 Oct;86(10):5060–6.

References

  • Kenemans P, A Bosman. Breast cancer and post-menopausal hormone therapy. Best Pract Res Clin Endoc Metab 2003;17/1:123–137.

References

  • Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11.
  • Kessel B, Kronenberg F. The role of complementary and alternative medicine in management of menopausal symptoms. Endocrinol Metabl Clin N Am 2004;33:717.
  • Tice JA, Ettinger B, Ensrud K et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290:207.
  • Osmers R, Friede M, Liske E et al. Efficacy and safety of isopropanolic Black Cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074.
  • Suvanto-Luukkonene E, Koivunen R, Sundstrom H et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18.
  • Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059.
  • Guttuso T, Kurlan R, McDermott MP et al. Gabapentin’s effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gyencol 2003;101:337.

References

  • Kuehn BM. Better osteoporosis management a priority: impact predicted to soar with aging population.JAMA. 2005 May 25;293(20):2453–8.
  • Stokstad E. Bone quality fills holes in fracture risk. Science. 2005 Jun 10;308(5728):1580.
  • Miller PD, Siris ES, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Chen YT, Berger ML, Santora AC, Sherwood LM Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002 Dec;17(12):2222–30.
  • Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF. Differential Effects of Teripara-tide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorpho-metric Parameters. Bone Miner Res. 2005 Jul;20(7):1244–1253. Epub 2005 Mar 14.
  • Doggrell SA. Present and future pharmacotherapy for osteoporosis. Drugs Today (Barc). 2003 Aug;39(8):633–57.

References

  • Panay N, Studd JWW. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Upd 1997;3(2):159–171.
  • Studd JWW, Panay N. Hormones and Depression in Women. Climacteric 2004;7(4):338–46.
  • Raudaskoski T, et al. Intrauterine 10 mcg and 20 mcg levonorgestrel systems in postmenopausal women receiving oral HRT: clinical, endometrial and metabolic response. BJOG. 2002;109(2):136–44.
  • Rubig A. Drospirenone: a new cardiovascular active progestin with anti-aldosterone and anti androgenic properties. Climacteric 2003; S3: 49–54.
  • de Gooyer ME, et al. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183(1–2):55–62.
  • Ronkin S, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women Obstet Gynaecol 2005; 105(6) 1397–404.
  • Chabbert-Buffet N, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Upd 2005;11(3):293–307.

References

  • Garrido-Latorre F, Lazcano-Ponce EC, López-Carillo L, Hernández-Avila M. Age of natural menopause among women in México City. Int J Gynaecol Obstet 1996;53:159–66.
  • Sierra B, Hidalgo LA, Chedraui PA. Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale. Maturitas 2005; In press
  • Palacios S. Current perspectives on the benefits of HRT in menopausal women. Maturitas 2000;35:3–9.
  • Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191–210.
  • Blumel JE, Castelo-Branco C, Riquelme R, Araya H, Jaramillo P, Tacla X et al. Use of hormone replacement therapy among Chilean women: a comparison between socioeconomic levels. Menopause 2002;9:377–80.
  • The Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principles results from the Women’s Health Initiative randomized controlled trial JAMA 2002;288:321–33.
  • Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, Sarra S. Patients’ and clinicians’ attitudes after the Women’s Health Inititative study. Menopause 2004;11:57–61.
  • Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37–43.
  • Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994;49:153–160.
  • Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon [sup]1[/sup]) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001;78:67–75.
  • Lichtenstein AH. Soy protein, isoflavon and cardiovascular disease risk. J Nutr 1998;128:1589–1592.
  • Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ Health Perspect 1998;106:807–812.
  • van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187–93.
  • Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259–65.
  • Knudson TM, Ensrud KE, Blackwell T, Ettinger B, Wallace R, Tice JA. Effect of isoflavones on lipids and bone turnoever markers in menopausal women. Maturitas 2004;48:209–18.
  • Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double blind, randomized, placebo controlled trial. Am J Clin Nutr 2004;79:326–33.
  • Jeri AR. The use of an isoflavone supplement to relive hot flushes. The Female Patient 2002;27:35–7.
  • Hidalgo L, Chedraui P, Morocho N, Ross S, San Miguel G. [The beneficial effects of isoflavones derived from red clover extracts over vagina, lipid profile and symptoms in menopausal women]. Rev Medicina 2005; in press

References

References

References

References

  • Ettinger B. et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 2000;104:443–451.
  • Johnson S.R. et al. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779–87.
  • Prestwood K.M. et al. Ultralow-dose micronized 17bestradiol and bone density and bone metabolism in older women. A randomized controlled trial. JAMA 2003;290:1042–1048.
  • Steinberg K. et al. Poster presented at the 26th American Society for Bone and Mineral Research 2004.

Reference

References

  • Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133–44.
  • Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138(3):168–75.
  • Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 25;289(24):3243–53.
  • Chlebowski RT, McTiernan A. Biological significance of interventions that change breast density. J Natl Cancer Inst 2003;95(1):4–5.
  • Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95(1):30–7.
  • Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186(4):717–22.
  • McTiernan A, Martin C, Peck JD, et al. For the Women’s Health Initiative Mammogram Density Study Investigators. Estrogen Plus Progestin Influence on Mammogram Density in Healthy Postmenopausal Women in the Women’s Health Initiative Randomized Trial. JNCI 2005 (provisional acceptance).
  • The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004;291(14):1701–14.
  • Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288(3):321–33.

References

  • de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;21–30.
  • Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas 2004;S5-S15.
  • Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J.Steroid Biochem.Mol.Biol. 1994;311–8.
  • Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil.Steril. 2004;617–23.
  • Conner P, Christow A, Kersemaekers W, Soderqvist G, Skoog L, Carlstrom K, Tani E, Mol-Arts M, von Schoultz B. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric. 2004;50–8.
  • von Schoultz B. The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammo-graphic density. Maturitas 2004;S16-S21.
  • Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gyn 2005;228–33.

References

  • NAMS. Treatment of menopause-associated vasomotor symptoms. Menopause 2004;11:11–33.
  • Stearns V, et al. Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA 2003:2827–34.
  • Loprinzi C, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–83.
  • Suvanto-Luukkonen E, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26.
  • Loprinzi C, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63.
  • Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002:805–13.
  • Whiteman M, et al. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264–72.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.